Table 2.
Raw values of pain and WOMAC, mean ± SD (95% CI) at baseline and follow-up (mITT)
| Baseline
|
3 m
|
6 m
|
9 m
|
12m
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HA | BM | HA | BM | HA | BM | HA | BM | HA | BM | |
| Global pain | 6.1±0.62* (6.0–6.3) |
6.6±1.03 (6.4–6.8) |
3.1±0.9 (3.0–3.3) |
2.2±1.1** (2.0–2.5) |
2.4±1.0 (2.2–2.6) |
3.9±0.7 (3.8–4.0) |
3.6±1.1 (3.4–3.8) |
5.5±0.7 (5.4–5.6) |
4.1±0.8 (3.9–4.2) |
6.0±0.9 (5.8–6.1) |
| WOMAC | ||||||||||
| Total (0–96) | 74.0±3.8 (73.3–74.9) |
68.2±4.1 (67.5–69.1) |
23.2±6.9 (21.9–24.7) |
34.5±5.5 (33.4–35.7) |
19.4±7.5 (18.0–21.0) |
42.3±4.7 (41.5–43.3) |
35.0±5.9 (33.9–36.3) |
59.3±5.0 (58.4–60.4) |
39.6±6.3 (38.4041.0) |
59.3±5.0 (58.4–60.4) |
| Pain (0–20) | 15.3±2.7 (14.8–15.8) |
14.8+3.1 (14.2–15.4) |
2.4±2.3 (2.0–2.9) |
7.4±2.2 (6.9–7.9) |
1.5±2.2 (1.1–2.0) |
9.7±2.6 (9.1–10.2) |
7.0±2.0 (6.6–7.4) |
12.8+3.1 (12.1–13.4) |
8.3±2.5 (7.8–8.8) |
12.8+3.1 (12.2–13.5) |
| Function (0–68) | 53.2±4.0 (52.4–54.0) |
48.4±4.8 (47.4–49.3) |
19.1±4.6 (18.2–20.1) |
24.9±4.8 (24.0–25.9) |
I6.9±4.8 (16.0–17.9) |
29.3±4.3 (28.4–30.1) |
25.0±4.5 (24.1–25.9) |
41.8±5.0 (40.8–42.8) |
27.8±4.6 (26.9–28.7) |
41.9±4.9 (40.9–42.8) |
| Stiffness (0–8) | 5.6+1.5 (4.2–4.8) |
5.4±1.9 (5.0–5.8) |
1.7±1.3 (1.4–2.0) |
2.2+1.6 (1.9–2.5) |
1.1±1.1 (0.8–1.3) |
3.4+1.5 (3.1–3.7) |
3.0+1.2 (2.8–3.3) |
4.6±1.4 (4.3–4.9) |
3.6+1.2 (3.3–3.8) |
4.5±1.4 (4.2–4.8) |
Notes: P-values: <0.0001 in favor of HA in all the comparison between groups except or
*
P=0.004 in favor of HA, and
**
P<0.0001 in favor of BM.
Abbreviations: BM, betamethasone; CI, confidence interval; HA, hyaluronic acid; mITT, modified intention to treat; SD, standard deviation; WOMAC, Western Ontario McMaster University Osteoarthritis.